LU90366I2 - Nasonex - Google Patents

Nasonex

Info

Publication number
LU90366I2
LU90366I2 LU90366C LU90366C LU90366I2 LU 90366 I2 LU90366 I2 LU 90366I2 LU 90366 C LU90366 C LU 90366C LU 90366 C LU90366 C LU 90366C LU 90366 I2 LU90366 I2 LU 90366I2
Authority
LU
Luxembourg
Prior art keywords
nasonex
compound
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
LU90366C
Other languages
English (en)
French (fr)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90366(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of LU90366I2 publication Critical patent/LU90366I2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
LU90366C 1990-09-10 1999-03-05 Nasonex LU90366I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10

Publications (1)

Publication Number Publication Date
LU90366I2 true LU90366I2 (fr) 1999-05-05

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90366C LU90366I2 (fr) 1990-09-10 1999-03-05 Nasonex

Country Status (35)

Country Link
US (1) US6180781B1 (es)
EP (1) EP0548114B1 (es)
JP (1) JPH0725789B2 (es)
KR (1) KR960013445B1 (es)
CN (1) CN1030920C (es)
AT (1) ATE113604T1 (es)
AU (1) AU663471B2 (es)
BG (1) BG60755B2 (es)
CA (1) CA2091360C (es)
CZ (1) CZ281318B6 (es)
DE (2) DE69104991T2 (es)
DK (1) DK0548114T5 (es)
EE (1) EE02962B1 (es)
ES (1) ES2065701T3 (es)
FI (1) FI111078B (es)
HK (1) HK185996A (es)
HR (1) HRP920383B1 (es)
HU (1) HU213401B (es)
IE (1) IE67056B1 (es)
IL (1) IL99437A (es)
LU (1) LU90366I2 (es)
MX (2) MX9203396A (es)
MY (1) MY106644A (es)
NL (1) NL980012I2 (es)
NO (1) NO300548B1 (es)
NZ (1) NZ239711A (es)
OA (1) OA09772A (es)
PH (1) PH30443A (es)
PL (1) PL165803B1 (es)
PT (1) PT98905B (es)
SI (1) SI9111497A (es)
TW (2) TW272195B (es)
WO (1) WO1992004365A1 (es)
YU (1) YU48666B (es)
ZA (1) ZA917148B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213401B (en) * 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
CA2305256C (en) * 1997-10-09 2005-05-17 Schering Corporation Mometasone furoate suspensions for nebulization
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
NZ545748A (en) * 2003-08-29 2010-03-26 Ranbaxy Lab Ltd Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス,インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
HU213401B (en) * 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it

Also Published As

Publication number Publication date
NZ239711A (en) 1992-09-25
DE19875032I2 (de) 2007-04-19
HRP920383B1 (en) 2000-04-30
NO930693D0 (no) 1993-02-26
YU149791A (sh) 1994-01-20
PH30443A (en) 1997-05-09
IE67056B1 (en) 1996-02-21
SI9111497A (sl) 1998-04-30
HU9300685D0 (en) 1993-06-28
CA2091360C (en) 1997-04-08
WO1992004365A1 (en) 1992-03-19
IL99437A (en) 1995-05-29
HU213401B (en) 1997-06-30
DK0548114T5 (da) 1995-01-30
IL99437A0 (en) 1992-08-18
FI931031A0 (fi) 1993-03-09
MX9203396A (es) 1992-07-31
AU8497491A (en) 1992-03-30
DE69104991T2 (de) 1995-04-20
KR960013445B1 (ko) 1996-10-05
DE69104991D1 (de) 1994-12-08
IE913155A1 (en) 1992-03-11
TW229208B (es) 1994-09-01
ZA917148B (en) 1992-08-26
CZ38393A3 (en) 1994-01-19
YU48666B (sh) 1999-06-15
NL980012I1 (nl) 1998-05-06
CN1059911A (zh) 1992-04-01
JPH05506667A (ja) 1993-09-30
OA09772A (en) 1993-11-30
HUT64361A (en) 1993-12-28
MX9100990A (es) 1992-05-04
NO300548B1 (no) 1997-06-16
CA2091360A1 (en) 1992-03-11
FI931031A (fi) 1993-03-09
FI111078B (fi) 2003-05-30
PT98905A (pt) 1992-09-30
HK185996A (en) 1996-10-11
PL165803B1 (pl) 1995-02-28
CN1030920C (zh) 1996-02-07
JPH0725789B2 (ja) 1995-03-22
MY106644A (en) 1995-07-31
AU663471B2 (en) 1995-10-12
TW272195B (es) 1996-03-11
EP0548114B1 (en) 1994-11-02
EE02962B1 (et) 1997-02-17
ES2065701T3 (es) 1995-02-16
CZ281318B6 (cs) 1996-08-14
BG60755B2 (bg) 1996-02-29
EP0548114A1 (en) 1993-06-30
US6180781B1 (en) 2001-01-30
NO930693L (no) 1993-02-26
HRP920383A2 (en) 1998-06-30
NL980012I2 (nl) 2004-11-01
PT98905B (pt) 1998-08-31
ATE113604T1 (de) 1994-11-15

Similar Documents

Publication Publication Date Title
LU90366I2 (fr) Nasonex
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
SE8300736D0 (sv) Novel pharmacologically active compounds
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
GB8823567D0 (en) 4h-1-benzopyran-4-one derivative/its salt & process for producing same
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
NZ192195A (en) 1-triazolyl-2-hydroxy-2-phenyl-3-aryl-propanes and pharmaceutical compositions
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
NO903291D0 (no) Renin-hemmende aminooligohydroksy-derivater.
ES474052A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridazinas 1-n-sustituidas.
IL66192A (en) Albomycin derivatives,their production and pharmaceutical compositions containing them
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
ES444600A1 (es) Un procedimiento de obtencion de los 3-azadiespirodecanos.
IT1255696B (it) Composto con attivita' vasodilatatrice procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
RU94019328A (ru) α- ГЕТЕРОАРИЛОКСИМЕТИЛКЕТОНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИНГИБИРУЮЩАЯ ИНТЕРЛЕЙКИН-1 - β -ПРОТЕАЗУ
JO1711B1 (en) Therapeutic agents